Mobile

A phase IIIb/IV randomised, controlled study evaluating an intensification treatment strategy of adding enfuvirtide (ENF) to an oral Highly Active AntiRetroviral Therapy (HAART) in treatment experienc...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004358-24

A phase IIIb/IV randomised, controlled study evaluating an intensification treatment strategy of adding enfuvirtide (ENF) to an oral Highly Active AntiRetroviral Therapy (HAART) in treatment experienced patients

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To evaluate the induction strategy of HAART alone (I1) compared to enfuvirtide (90 mg s.c.BID) in combination with HAART (ENF+HAART, I2) • To determine the overall induction/maintenance treatment strategy (with or without continued ENF) after 48 weeks of treatment • To compare different maintenance strategies for those patients who are qualified for entering the maintenance phase (M1, M2 and M3) • To assess the safety of induction phase (I1 vs I2) and maintenance phase (M1, M2, and M3).

Critère d'inclusion

  • HIV infection

Liens